Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MacroGenics (MGNX)
NASDAQ:MGNX
Holding MGNX?
Track your performance easily
MGNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.14 - $21.88
Previous Close$3.37
Volume613.16K
Average Volume (3M)1.05M
Market Cap
$211.06M
Enterprise Value$161.19M
Total Cash (Recent Filing)$83.93M
Total Debt (Recent Filing)$34.06M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 06, 2024EPS Estimate
$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding62,722,244
10 Day Avg. Volume708,552
30 Day Avg. Volume1,048,478
Standard Deviation0.32
R-Squared0.12
Alpha-0.00628
Financial Highlights & Ratios
Price to Book (P/B)3.66
Price to Sales (P/S)5.45
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.08
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$7.25Price Target Upside119.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
MacroGenics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe topline data from the Phase II TAMARACK trial assessing optimized vobra duo doses showed promising initial PSA50 responses.
Financial MilestonesMGNX ended 2Q24 with $140.4M in cash and equivalents and subsequently received a $100.0M milestone payment from INCY.
Future ProspectsOverlooked strength to topline efficacy holds promise to get even better, warranting of further B7-H3 target de-risking in earlier lines, as part of immunotherapy combination, and additional tumor types.
Bears Say
Discontinuation Of TreatmentThe discontinuation of further dosing of vobramitamab duocarmazine (vobra duo) in the TAMARACK trial in metastatic castration-resistant prostate cancer (mCRPC) was based on the recommendation of the study's data monitoring committee.
Financial PerformanceMacroGenics reported its 1Q24 net loss of $0.89 per share, wider than the previous forecast of a net loss of $0.70 per share.
Safety ConcernsSafety deteriorated from the abstract, raising material questions about the timing and nature of the reported fatalities.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MGNX FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was $3.14 and its highest was $21.88 in the past 12 months.
What is MacroGenics’s market cap?
Currently, no data Available
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Aug 06, 2024. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.661 by -$0.229.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is $0.21.
How many shares outstanding does MacroGenics have?
MacroGenics has 62,722,244 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.661. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of MacroGenics?
Among the largest hedge funds holding MacroGenics’s share is RA Capital Management. It holds MacroGenics’s shares valued at 9M.
---
MacroGenics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.25 (119.70% Upside)
$7.25 (119.70% Upside)
Blogger Sentiment
Bullish
MGNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 408.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.78%
12-Months-Change
Fundamentals
Return on Equity
-118.91%
Trailing 12-Months
Asset Growth
-34.19%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
---
MGNX Earnings Call
Q1 2024
0:00 / 0:00
---
MGNX Stock 12 Month Forecast
Average Price Target
$7.25
▲(119.70% Upside)
Technical Analysis
Best Analysts Covering MGNX
1 Year
1 Year Success Rate
8/26 ratings generated profit
1 Year Average Return
-15.97%
reiterated a buy rating last month
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -15.97% per trade.
---